Executive record

Polly A. Murphy, DVM, PhD

Director at Atea Pharmaceuticals, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:polly-a-murphy-dvm-phdVersion: public-0As of: 2026-09-30

Not yet claimed9 published Claims3 sources
  • Director

Key Claims

Biography

Dr. Polly Murphy brings more than three decades of life science industry experience spanning academia, pharmaceutical and biopharmaceutical companies. Her expertise includes commercial development, strategic planning, R&D, and business development, with notable success in pipeline development and commercialization at Pfizer.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Chief Business Officer · Organization not publishedAVIR DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. AVIR DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 15, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Nominating/Governance, Strategy and Public Policy · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Avadel Pharmaceuticals plc · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Business Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Atea Pharmaceuticals, Inc. · Claim reviewed: May 15, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Atea Pharmaceuticals, Inc. · Claim reviewed: May 15, 2026